Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Glaucoma in perspective

- PMLiVE

India denies Vertex patent on cystic fibrosis drug Orkambi

Says treatment is neither innovative or more effective than its predecessor

- PMLiVE

Zytoprotec expands supervisory board

Prof Joerg Vienken and Prof Norbert Riedel join the firm

Merck’s Michel Vounatsos moves to Biogen

He takes up the roles of executive vice president and chief commercial officer

- PMLiVE

Jazz Pharma bags FDA approval for rare disease drug

Defitelio given the green light to treat patients who develop severe hepatic VOD

Bristol Myers Squibb logo

Opdivo edges closer to first haematological cancer indication

EMA begins review of BMS' classic Hodgkin’s lymphoma inhibitor treatment

- PMLiVE

Mark Booth joins Probiodrug

He becomes chief business officer

Quality Context appoints technical manager and QP

David Franks brings experience from Reckitt Benckiser

- PMLiVE

Are you experienced?

Identifying and exceeding customer expectations remains a work-in-progress for pharma

HQ digital marketing: Trouble-free localization

Adapt HQ content to local markets without stress following these 10 steps

Anthill Agency

B2B social media: a spring 2016 review

Is your social media strategy on point? Take a look at the latest trends in B2B social media.

Say Communications

- PMLiVE

Adjusting to change in healthcare: Learning from translational research

In this article, Blue Latitude Health's Head of Insight, Martine Leroy, explores how pharma could learn from translational research organisations in adapting their approach to the changing healthcare landscape.

Blue Latitude Health

- PMLiVE

Nuplazid backed by FDA panel as first-ever Parkinson’s psychosis drug

Concludes Acadia Pharmaceuticals’ drug provides ‘modest but meaningful’ benefits

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links